Equities

Aprea Therapeutics Inc

APRE:NAQ

Aprea Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.55
  • Today's Change-0.43 / -10.80%
  • Shares traded57.21k
  • 1 Year change-12.78%
  • Beta0.9391
Data delayed at least 15 minutes, as of Nov 08 2024 20:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.

  • Revenue in USD (TTM)1.31m
  • Net income in USD-13.51m
  • Incorporated2019
  • Employees7.00
  • Location
    Aprea Therapeutics Inc3805 OLD EASTON ROADDOYLESTOWN 18902United StatesUSA
  • Phone+1 (617) 463-9385
  • Fax+1 (302) 655-5049
  • Websitehttps://www.aprea.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Microbot Medical Inc0.00-10.44m16.83m22.00--2.69-----0.81-0.810.000.37930.00----0.00-113.94-53.28-133.34-62.65------------0.00------18.44---31.76--
Synlogic Inc3.17m-56.16m16.92m6.00--1.06--5.34-7.24-7.240.35491.370.0628----528,333.30-111.31-40.57-131.17-43.82-----1,771.74-3,245.93----0.00--185.685.9913.40---48.05--
Kairos Pharma Ltd0.00-2.01m17.21m-----------0.1562-0.15620.00-0.20670.00-------199.80-----------------15.58---------72.57------
Lyra Therapeutics Inc1.82m-101.39m17.52m87.00--0.5655--9.62-1.61-1.610.02940.47330.0165----20,681.82-92.07-58.01-108.51-68.69-----5,570.88-6,235.31----0.00--14.314.60-13.39--95.14--
Kazia Therapeutics Ltd (ADR)14.84k-13.47m17.76m12.00--1.65--1,196.48-8.17-8.170.00813.480.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Cocrystal Pharma Inc0.00-17.93m17.91m12.00--1.03-----1.76-1.760.001.710.00----0.00-61.98-50.94-66.88-52.77-------1,501.78----0.00------53.69--33.34--
Finch Therapeutics Group Inc0.00-14.17m18.95m18.00--1.33-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Aprea Therapeutics Inc1.31m-13.51m19.28m7.00--0.8791--14.71-2.81-2.810.26464.280.0498----187,262.90-51.30-68.66-60.22-77.19-----1,030.42-42,112.84----0.00------87.32--90.61--
Calidi Biotherapeutics Inc0.00-24.92m19.62m41.00---------5.41-5.410.00-1.820.00----0.00-279.89-----------------27.58-----100.00---14.90------
Unity Biotechnology Inc0.00-19.05m19.71m19.00--1.39-----1.14-1.140.000.83940.00----0.00-32.73-47.21-38.49-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Goldenwell Biotech Inc940.00-137.11k19.80m----5,169.71--21,063.83-0.0014-0.00140.000010.000040.00480.0031-----69.82---70.29--42.55---14,586.17--21.43--0.00---95.10--88.13------
NanoViricides Inc0.00-8.29m20.08m7.00--1.65-----0.698-0.6980.000.87220.00----0.00-55.81-43.88-59.61-46.26------------0.00------3.43--16.23--
MEI Pharma Inc65.30m17.78m20.26m28.001.140.61341.120.31022.672.679.804.960.8052--1,536.402,332,036.0021.92-21.0926.64-23.99----27.23-72.23----0.00--33.7667.75155.84---49.68--
Cognition Therapeutics Inc0.00-31.08m20.27m25.00--0.8804-----0.9317-0.93170.000.57360.00----0.00-79.36---104.49-------------263.290.00-------20.52------
Promis Neurosciences Inc0.00-12.20m21.54m6.00---------0.6924-0.69240.00-0.12010.00----0.00-839.15-144.28---262.23-------2,271,047.00------------26.85------
Data as of Nov 08 2024. Currency figures normalised to Aprea Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

40.87%Per cent of shares held by top holders
HolderShares% Held
AIGH Capital Management LLCas of 30 Jun 2024539.30k9.93%
Stonepine Capital Management LLCas of 07 Oct 2024365.44k6.73%
Sio Capital Management LLCas of 30 Jun 2024276.60k5.09%
Sphera Funds Management Ltd.as of 30 Jun 2024270.00k4.97%
Nantahala Capital Management LLCas of 30 Jun 2024205.76k3.79%
Altium Capital Management LPas of 30 Jun 2024137.20k2.53%
DAFNA Capital Management LLCas of 30 Jun 2024137.17k2.53%
Exome Asset Management LLCas of 30 Jun 2024137.17k2.53%
The Vanguard Group, Inc.as of 30 Jun 2024115.84k2.13%
Geode Capital Management LLCas of 30 Jun 202435.67k0.66%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.